ReleaseWire Connect

BioCorRx Inc. (OTCMKTS:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced positive preliminary data from preclinical studies evaluating BICX101, a sustained release, injectable naltrexone for the treatment of opioid abuse and alcoholism. Thus far, in the preclinical studies, the product is successfully delivering above adequate sustained release levels of naltrexone. The study has so far confirmed a number of the expected advantages of BICX101.The Company is also expecting Innovative Science Solutions (ISS) to finalize and submit the Pre-IND meeting request application in the first week of April.

BioCorRx Inc. (OTCMKTS:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, announced today that it will be presenting at the Sidoti & Company Spring 2017 Convention on Wednesday, March 29th at 8:40 AM ET at the New York Marriott Marquis in Times Square. Brady Granier, President and CEO, and Lourdes Felix, CFO and COO, will be presenting and holding one-on-one meetings with investors throughout the day.

BioCorRx Inc. (OTCMKTS:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that it has completed an equity financing of $940,000 with accredited investors. The Company also announced Alpine Creek Capital Partners has agreed to invest another $1,660,000 by March 24, 2017, totaling an aggregate investment of $4,160,000. The Company received an initial investment of $2,500,000 from Alpine Creek Capital on June 10, 2016. Details of the transaction can be found in the Company's filings with the Securities and Exchange Commission.

BioCorRx Inc. (OTC:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today provided an update on the preclinical development of BICX101, a new sustained release injectable naltrexone product for the treatment of substance abuse addiction, via a webcast that is available on the News & Media section ("Presentation" subpage) of the Company's website: www.BioCorRx.com.

BioCorRx Inc. (OTCMKTS:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Dr. Balbir S. Brar has been appointed VP of Drug Development for the BioCorRx Pharmaceuticals subsidiary. Previously, Dr. Brar served as lead drug development study design consultant for the BioCorRx Pharmaceuticals subsidiary.

JGR Capital Partners, a leading equity research and digital investor relations firm, has announced it has released an update on BioCorRx (OTCMKTS:BICX).

BioCorRx Inc. (OTCMKTS:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today provided a business update via webcast that is available on the News & Media section of the Company's website: http://www.BioCorRx.com. The presentation includes an overview of the market, the Company's pharmaceutical pipeline, its regulatory and clinical strategy, and an update on the roll-out of the Company's BioCorRx® Recovery Program.

BioCorRx Inc. (OTC PINK: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced it will assist the city of Anaheim, California, in treating residents with opioid and alcohol addiction. The collaboration was discussed by Anaheim Mayor Tom Tait during his seventh State of the City address on February 7th in Anaheim.

BioCorRx Inc. (OTC:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced it has retained Innovative Science Solutions, LLC, ("ISS") a leading scientific consulting firm, headquartered in Morristown, New Jersey to help guide the Company's regulatory strategy for the submission of its sustained release naltrexone product(s) to the U.S. Food and Drug Administration (FDA).  The company's injectable naltrexone product, BICX101 is being developed under its BioCorRx Pharmaceuticals subsidiary in partnership with TheraKine, Ltd and is currently in preclinical development. The company also owns two, already developed, naltrexone pellet products which are implanted subcutaneously.

BioCorRx Inc. (OTCPINK:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, announced today it will host a virtual webinar at 2:00 p.m. Eastern time (11:00 a.m. Pacific time) on Wednesday, October 12, 2016.